Equities research analysts expect Hill-Rom Holdings, Inc. (NYSE:HRC) to post earnings per share of $0.98 for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Hill-Rom’s earnings. The lowest EPS estimate is $0.98 and the highest is $0.99. Hill-Rom posted earnings per share of $0.92 in the same quarter last year, which suggests a positive year-over-year growth rate of 6.5%. The business is scheduled to announce its next quarterly earnings results on Friday, January 25th.
On average, analysts expect that Hill-Rom will report full-year earnings of $5.13 per share for the current fiscal year, with EPS estimates ranging from $5.12 to $5.16. For the next year, analysts expect that the company will post earnings of $5.73 per share, with EPS estimates ranging from $5.68 to $5.77. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Hill-Rom.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.12. The firm had revenue of $759.20 million during the quarter, compared to the consensus estimate of $750.90 million. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. The business’s revenue was up 2.8% compared to the same quarter last year. During the same period last year, the company earned $1.32 earnings per share.
HRC stock traded down $2.99 during mid-day trading on Monday, reaching $92.76. The company had a trading volume of 494,073 shares, compared to its average volume of 400,213. The company has a quick ratio of 1.30, a current ratio of 1.74 and a debt-to-equity ratio of 1.11. Hill-Rom has a 52 week low of $78.16 and a 52 week high of $99.81. The company has a market cap of $6.44 billion, a price-to-earnings ratio of 19.53, a P/E/G ratio of 1.33 and a beta of 0.94.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Investors of record on Friday, December 14th will be paid a $0.20 dividend. The ex-dividend date is Thursday, December 13th. This represents a $0.80 annualized dividend and a yield of 0.86%. Hill-Rom’s dividend payout ratio (DPR) is presently 16.84%.
In related news, SVP Andreas G. Frank sold 7,454 shares of the business’s stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $95.76, for a total value of $713,795.04. Following the completion of the sale, the senior vice president now directly owns 27,224 shares in the company, valued at approximately $2,606,970.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.90% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP boosted its stake in Hill-Rom by 179.2% in the 3rd quarter. Marshall Wace LLP now owns 332,231 shares of the medical technology company’s stock valued at $31,363,000 after purchasing an additional 213,243 shares during the period. Vanguard Group Inc. boosted its stake in Hill-Rom by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 5,916,827 shares of the medical technology company’s stock valued at $558,549,000 after purchasing an additional 34,369 shares during the period. Morgan Stanley boosted its stake in Hill-Rom by 61.5% in the 3rd quarter. Morgan Stanley now owns 298,561 shares of the medical technology company’s stock valued at $28,185,000 after purchasing an additional 113,706 shares during the period. Nordea Investment Management AB boosted its stake in Hill-Rom by 36.1% in the 3rd quarter. Nordea Investment Management AB now owns 49,577 shares of the medical technology company’s stock valued at $4,680,000 after purchasing an additional 13,139 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its stake in Hill-Rom by 2.1% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 192,606 shares of the medical technology company’s stock valued at $18,182,000 after purchasing an additional 4,010 shares during the period. Institutional investors and hedge funds own 82.59% of the company’s stock.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: Risk Tolerance and Your Investment Decisions
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.